beta
Trial Radar AI
Clinical Trial NCT07193329 for Psychological Distress, Malignant Tumor is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Psychological Distress in Malignant Tumor Patients: Effects on Treatment Adherence, Outcomes, and Quality of Life 2,000 Observational

Recruiting
Clinical Trial NCT07193329 is an observational study for Psychological Distress, Malignant Tumor that is recruiting. It started on 22 July 2025 with plans to enroll 2,000 participants. Led by Gang Chen, MD, it is expected to complete by 1 July 2028. The latest data from ClinicalTrials.gov was last updated on 25 September 2025.
Brief Summary
The goal of this observational study is to learn about the Psychological Distress in Malignant Tumor Patients about Effects on Treatment Adherence, Outcomes, and Quality of Life. The main question it aims to answer is:

Does Psychological Distress affect Malignant Tumor Patients' Effects on Treatment Adherence, Outcomes, and Quality of Life? Malignant Tumor Patients with or without Psychological Distress will answer ...

Show More
Official Title

Psychological Distress in Malignant Tumor Patients: Effects on Treatment Adherence, Outcomes, and Quality of Life

Conditions
Psychological DistressMalignant Tumor
Other Study IDs
  • KY2025-235
NCT ID Number
NCT07193329
Start Date (Actual)
2025-07-22
Last Update Posted
2025-09-25
Completion Date (Estimated)
2028-07-01
Enrollment (Estimated)
2,000
Study Type
Observational
Status
Recruiting
Arms / Interventions
Participant Group/ArmIntervention/Treatment
Malignant Tumor Patients with Psychological Distress
N/A
Malignant Tumor Patients without Psychological Distress
N/A
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Objective Response Rate (ORR) by mRECIST (%)
Proportion of participants achieving complete response (CR) or partial response (PR) based on mRECIST criteria, measured on contrast-enhanced CT/MRI.
at 4-12 weeks after treatment initiation.
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • (1) Confirmed malignant tumors by imaging or pathology (such as hepatobiliary carcinoma, gastric cancer, breast cancer, lung cancer, etc.)
  • (2) Planning to receive or currently undergoing systemic treatment (such as surgery, chemotherapy, TACE, targeted therapy, etc.)
  • (3) Age ≥18 years old
  • (4) Sign the informed consent form and voluntarily participate in this study

  • (1) Combined with severe systemic diseases (such as severe cardiovascular and cerebrovascular diseases)
  • (2) There is severe cognitive impairment and it is impossible to complete the questionnaire assessment
  • (3) Incomplete clinical data or loss to follow-up
Gang Chen, MD logoGang Chen, MD
Study Responsible Party
Gang Chen, MD, Sponsor-Investigator, M.D., Ph.D., Professor, First Affiliated Hospital of Wenzhou Medical University
No contact data.
1 Study Locations in 1 Countries

Zhejiang

First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China
Gang Chen, MD, Contact, 86+13616619566, [email protected]
Recruiting